AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01536249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine plus Dexpramipexole
Description: Multiple Oral Doses
Study NCT03837405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet
Study NCT03837405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet
Study NCT03837405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfuless
Description: Mindful eating app use plus group sessions to learn mindfulness
Study NCT00360490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
Study NCT00360490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone acetate
Description: Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
Study NCT01085669 — intervention group
Intervention type: DEVICE
Intervention: Microbiological analysis of retained VEPTR Implants
Description: Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
Study NCT00726895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: 1 x 324 mg capsule
Study NCT00726895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: 2 x 324 mg capsules
Study NCT02269150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation (FMT)
Study NCT02269150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No fecal microbiota transplantation (FMT), routine management
Study NCT03115073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candiplus
Description: Administration of Candiplus
Study NCT03115073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Administration of Clotrimazole
Study NCT01837550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
Study NCT01837550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: The control group only had access to reading material.
Study NCT01722643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAxIM
Description: This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
Study NCT01722643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
Study NCT04000893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise session
Description: Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
Study NCT02303119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab IV
Description: intra-venous, 375 mg/m²
Study NCT02303119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab IV
Description: intra-venous, 375 mg/m²
Study NCT01913054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Injection
Study NCT01913054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection
Study NCT01913054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate Fat Emulsion Injection
Study NCT01913054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Study NCT01913054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Injection
Study NCT00381849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystone
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.
Study NCT00381849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystone
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.
Study NCT00381849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cystone
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.
Study NCT00381849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill (Placebo)
Description: Participants will take 2 pills, 2 times a day for 6 weeks.
Study NCT00381849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (Placebo)
Description: Participants will take 2 pills, 2 times a day for 6 weeks.
Study NCT03755739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Description: vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
Study NCT02303119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: sub-cutaneous, 1400 mg
Study NCT00448864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecallantide
Study NCT03755739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Description: vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
Study NCT01928537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib sodium
Study NCT02808611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Reduction of the ANS response
Study NCT02808611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01810172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital pleural drainage system
Description: Reusable device with disposable collection system for digital monitoring of air leak.
Study NCT01810172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry suction pleura drainage device
Description: Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
Study NCT00448864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04881513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Narrow Band Imaging
Description: Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)
Study NCT04881513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tongue sensitivity testing
Description: testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
Study NCT00247039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solgar Israel
Description: Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
Study NCT00247039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: placebo capsules
Study NCT01545310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354
Description: One dose of ABT-354
Study NCT03847012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
Study NCT01338597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic thyroidectomy
Description: endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
Study NCT03060265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Administrating Paracetamol IV pre-cesarean section
Study NCT03060265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Administrating SALINE IV pre-cesarean section
Study NCT01884623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01884623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT03303014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 Prolene, 5-0 Fast Absorbing Gut
Description: The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
Study NCT04881513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitiy of life
Description: Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire
Study NCT04881513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Threshold change
Description: Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery
Study NCT04881513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Taste
Description: Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
Study NCT02911935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral azithromycin
Description: Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
Study NCT03815916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Study NCT01981161 — intervention group
Intervention type: PROCEDURE
Intervention: biological samples and clinical data
Study NCT01200524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 20 mg tablet
Study NCT01200524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 50 mg tablet
Study NCT01200524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06499181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: The primary objective is to examine differences in post-operative opioid consumption between the two groups.
Study NCT02911935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension
Study NCT02650973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701
Study NCT02650973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study NCT01723917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoSERM tablet
Study NCT01723917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00570206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
Study NCT03930069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
Study NCT03930069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
Study NCT02270034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is added to Stupp method
Study NCT02464670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered IM followed by Electroporation
Study NCT02464670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4202
Description: INO-4202 delivered IM followed by Electroporation
Study NCT06499181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
Study NCT06499181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
Study NCT02464670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered ID followed by Electroporation
Study NCT00000373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olanzapine + fluoxetine
Study NCT00000373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo + fluoxetine
Study NCT02464670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4212
Description: INO-4212 delivered IM followed by Electroporation
Study NCT02464670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4212 + INO-9012
Description: INO-4212 + INO-9012 delivered IM followed by Electroporation
Study NCT02464670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201 + INO-9012
Description: INO-4201 + INO-9012 delivered ID followed by Electroporation
Study NCT01413412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair using full thickness skin graft
Description: 25 patients
Study NCT04347096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention.
Study NCT04347096 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Intervention
Description: The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
Study NCT00671567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
Study NCT00671567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
Study NCT00671567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
Study NCT00345033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 15-mg dose once a day for 8 weeks
Study NCT00345033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet placebo dose once a day for 8 weeks
Study NCT02970045 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, tissue, and other biological samples
Study NCT02970045 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of Cancer Risk Factors
Description: Ancillary studies
Study NCT02970045 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study NCT02970045 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02970045 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04511611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
Study NCT04511611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 10 mg as 1 x 10 mg film-coated tablet
Study NCT01413412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair using mesh
Description: 25 patients
Study NCT02797015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Description: Oral capsule daily
Study NCT00132639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative docetaxel-cisplatin combination chemotherapy
Description: Preoperative docetaxel-cisplatin combination chemotherapy
Study NCT00132639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative docetaxel monotherapy
Description: Preoperative docetaxel monotherapy
Study NCT04137432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 international units oxytocin.
Study NCT04137432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contains identical ingredients except for the peptide itself.
Study NCT00316771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 150mg
Description: 150mg po qd
Study NCT00316771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 25mg
Description: 25mg po bid
Study NCT00316771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 300mg
Description: 300mg po qd